GSK commits to five-year vaccine price freeze for countries graduating from GAVI Alliance support

UK pharma giant GlaxoSmithKline (LSE: GSK) has said it will freeze the prices of its vaccines for a period of five years for developing countries that graduate from GAVI Alliance support.

By committing to offer GAVI Alliance prices for vaccines against pneumococcal disease, rotavirus and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programs.

Since its formation in 2000, the GAVI Alliance has helped to fund the immunization of 440 million children in some of the world’s poorest countries. GSK notes that it is a long-standing partner of the Alliance and reserves its lowest prices for GAVI-eligible countries, which can be as low as one-tenth of prices in developed countries.